Gregor Schulz - Merck KGaA Member of the Supervisory Board
| MKKGY Stock | USD 32.34 0.71 2.24% |
Executive
Prof. Dr. Gregor Schulz is Member of the Supervisory Board of Merck KGaA since May 9, 2014. He serves as Member of the Board of Partners of E. Merck KG. He served Various head positions in the area of clinical research, and Member of the Board of Management at Behringwerke AG, among others. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck KGaA Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck KGaA's management efficiency ratios could be used to measure how well Merck KGaA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Reed McClung | Eagle Pharmaceuticals | N/A | |
| Robert Weingarten | Guardion Health Sciences | 72 | |
| Valentin MD | Eagle Pharmaceuticals | N/A | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Christopher Mutz | ANI Pharmaceuticals | 52 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Melissa Forst | Deciphera Pharmaceuticals LLC | N/A | |
| Jennifer Henry | Alpha Teknova | N/A | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| Dashyant Dhanak | Deciphera Pharmaceuticals LLC | 63 | |
| Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
| Katie Cox | Guardion Health Sciences | 54 | |
| Daniel Martin | Deciphera Pharmaceuticals LLC | 49 | |
| William CPA | Organogenesis Holdings | N/A | |
| Kevin Brodbeck | Deciphera Pharmaceuticals LLC | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Jennifer Larson | Deciphera Pharmaceuticals LLC | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck KGaA ADR Leadership Team
Elected by the shareholders, the Merck KGaA's board of directors comprises two types of representatives: Merck KGaA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck KGaA's management team and ensure that shareholders' interests are well served. Merck KGaA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck KGaA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Heinzel, CEO Board | ||
| Gerhard Schmitz, Head Accounting | ||
| Stefan Oschmann, Chairman of Executive Board and CEO | ||
| Constantin Fest, Head of Investor Relations | ||
| Michaela Glenck, Member of the Supervisory Board | ||
| Veit Ulshoefer, Member of the Supervisory Board, Employee Representative | ||
| Gabriele Eismann, Member of the Supervisory Board, Employee Representative | ||
| Peter Guenter, CEO Board | ||
| Wolfgang Buechele, Chairman of the Supervisory Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Anke Schenkel, Head of Group Controlling & Risk Management | ||
| Marcus Kuhnert, Member of the Executive Board, CFO | ||
| Siegfried Karjetta, Member of the Supervisory Board | ||
| Alexander Putz, Member of the Supervisory Board, Employee Representative | ||
| Friederike Rotsch, Group Compliance | ||
| Dietmar Oeter, Member of the Supervisory Board, Employee Representative | ||
| Dirk Toepfer, Chief Officer | ||
| Gregor Schulz, Member of the Supervisory Board | ||
| Theo Siegert, Member of the Supervisory Board | ||
| Constantin Birnstiel, Head of Group Communications | ||
| Edeltraud Glaenzer, Member of the Supervisory Board, Employee Representative | ||
| Kai Beckmann, Chief Administrative Officer, Member of the Executive Board | ||
| Helga RuebsamenSchaeff, Member of the Supervisory Board | ||
| Udit Batra, CEO Life Science, Member of the Executive Board | ||
| Michael Fletterich, Vice Chairman of the Supervisory Board, Employee Representative | ||
| Crocifissa Attardo, Member of the Supervisory Board, Employee Representative | ||
| Albrecht Merck, Member of the Supervisory Board | ||
| Mechthild Auge, Member of the Supervisory Board, Employee Representative | ||
| Belen Garijo, CEO Healthcare, Member of the Executive Board | ||
| Walter Galinat, CEO Performance Materials, Member of the Executive Board | ||
| Tobias Thelen, Member of the Supervisory Board | ||
| Isabel Paoli, Chief Strategy Officer, Head of Communications |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Merck KGaA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 92.22 B | |||
| Shares Outstanding | 2.17 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 33.17 X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 3.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck KGaA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Merck KGaA ADR information on this page should be used as a complementary analysis to other Merck KGaA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Merck Pink Sheet analysis
When running Merck KGaA's price analysis, check to measure Merck KGaA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck KGaA is operating at the current time. Most of Merck KGaA's value examination focuses on studying past and present price action to predict the probability of Merck KGaA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck KGaA's price. Additionally, you may evaluate how the addition of Merck KGaA to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |